TRUS and Biopsy: Practical Aspects

Hendrikx, Ad J.M.; Safarík, L; Hammerer, Peter

doi:10.1016/s0302-2838(02)00044-1

Cited by 4 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2), another important potential difference between the probes is their ability to hit a specific prostatic site in T1c cases when a biopsy template is used. It was previously reported that the prostate apex may be difficult to sample with the SF probe, while a greater sampling of tissue from the peripheral zone is possible with an EF probe [5]. However, the ability to sample a specific area is related more to the ability of the operator than to the mechanical characteristics of the probe.…”

Section: Discussionmentioning

confidence: 99%

Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study

Raber¹,

Scattoni²,

Gallina³

et al. 2011

BJU International

View full text Add to dashboard Cite

What ' s known on the subject? and What does the study add? The infl uence of transrectal probe system, end-fi re and side-fi re, has not been studied in detail. Using a sextant biopsy template it has been demonstrated a difference between end-fi re and side-fi re modes in 4 -10 ng/mL PSA interval population. No studies evaluated the results in extended biopsy templates before.This study adds the knowledge that end-fi re and side-fi re transrectal probe, which are the two probe systems to perform transrectal prostate biopsy, have similar results in terms of prostate cancer detection rate and can be indifferently employed in extended prostate biopsy templates used in daily practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study

Raber¹,

Scattoni²,

Gallina³

et al. 2011

BJU International

View full text Add to dashboard Cite

show abstract

Biomarker research in prostate cancer—towards utility, not futility

2011

View full text Add to dashboard Cite

The identification of an appropriate clinical question is critical for any biomarker project. Despite rapid advances in technology, few biomarkers have been forthcoming for prostate cancer. This could be because the clinical questions under investigation have not actually originated from clinical practice. These clinical questions are difficult to identify in the complex and heterogeneous pathogenesis of prostate cancer. In this Review, we have developed a prostate cancer 'roadmap' to identify the aspects of prostate cancer that may be amenable to biomarker discovery and serve as a guide for future projects in prostate cancer biomarker research.

show abstract

Targeting fibronectin for cancer imaging and therapy

2017

View full text Add to dashboard Cite

During cancer progression, the extracellular matrix (ECM) undergoes dramatic changes, which promote cancer cell migration and invasion. In the remodeled tumor ECM, fibronectin (FN) level is upregulated to assist tumor growth, progression, and invasion. FN serves as a central organizer of ECM molecules and mediates the crosstalk between the tumor microenvironment and cancer cells. Its upregulation is correlated with angiogenesis, cancer progression, metastasis, and drug resistance. A number of FN-targeting ligands have been developed for cancer imaging and therapy. Thus far, FN-targeting imaging agents have been tested for nuclear imaging, MRI, and fluorescence imaging, for tumor detection and localization. FN-targeting therapeutics, including nuclear medicine, chemotherapy drugs, cytokines, and photothermal moieties, were also developed in cancer therapy. Because of the prevalence of FN overexpression in cancer, FN targeting imaging agents and therapeutics have the promise of broad applications in the diagnosis, treatment, and image-guided interventions of many types of cancers. This review will summarize current understanding on the role of FN in cancer, discuss the design and development of FN-targeting agents, and highlight the applications of these FN-targeting agents in cancer imaging and therapy.

show abstract

TRUS and Biopsy: Practical Aspects

Cited by 4 publications

References 40 publications

Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study

Does the transrectal ultrasound probe influence prostate cancer detection in patients undergoing an extended prostate biopsy scheme? Results of a large retrospective study

Biomarker research in prostate cancer—towards utility, not futility

Targeting fibronectin for cancer imaging and therapy

Contact Info

Product

Resources

About